arrow
C

Caterina Aversa

hospital universitario de vigo
H指数:15
被引数:1,187

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]

勘误:“接受雄激素受体通路抑制剂治疗的有转移性激素敏感性前列腺癌患者中RB1、PTEN和TP53基因的预后表达特征”[Eur. Urol. Open Sci. 70 (2024) 86–90]

2025-06-040
OA
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

雄激素受体途径抑制剂治疗的转移性激素敏感型前列腺癌患者RB1、PTEN和TP53基因的预后表达特征

2024-12-011
PRE
Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients

肿瘤抑制基因特征可预测转移性激素敏感性前列腺癌(mHSPC)患者的早期进展

2024-09-010
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA
Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
2023-10-010
PRE
HER3 Is an Actionable Target in Advanced Prostate Cancer
2021-11-0931
OAAI
TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
2021-09-010
OAAI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
2021-02-0186
OAAI
Elucidating Durable Responses to Immune Checkpoint Inhibition
2020-10-012
PREAI
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
2019-11-0154
OAAI